UNSPSC 51431806: Methyldopa anhydrous

This classification denotes a dopamine agonist and antihypertensive agent with the molecular formula C10H13NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M4R0H12F6M, chemically known as l-3-(3,4-dihydroxyphenyl)-2-methylalanine, but more generally known as methyldopa anhydrous, which bears US NIH Compound Identifier 4138. European Medicines Agency schedules methyldopa anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08867MIG.

Most nations, for tariff purposes, schedule methyldopa anhydrous under HS 29225000. SMILES: C[C@](CC1CCC(C(C1)O)O)(C(=O)O)N.

UNSPSC 51431806 Methyldopa anhydrous is a Commodity code representing specific pharmaceutical active ingredients and formulations that state and local governments procure for emergency medical services, public health programs, and institutional healthcare delivery. The recent opportunities under this code show state and local issuing bodies purchasing advanced life support medications, generic pharmaceuticals, and over-the-counter products through direct competitive solicitations and cooperative purchasing vehicles. The City of Tampa's Fire Rescue department, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the current buyer mix—municipal emergency services, state health agencies, and multi-state cooperative purchasing consortia working to supply medications across facilities and jurisdictions. Scope of work centers on pharmaceutical supply chain management, including vendor qualification for cGMP and Drug Supply Chain Security Act compliance, maintenance of expiration-date requirements and shelf-life standards, logistics and delivery scheduling, and pricing transparency through wholesaler networks or direct-to-manufacturer channels.

Activity concentrates in Florida, Texas, and Minnesota as of early 2026, with the Minnesota cooperative extending reach to Oregon and other participating jurisdictions. Representative recent opportunities include the City of Tampa's sealed-bid IFB (26P00188) for advanced life support medications—Labetalol, Epinephrine, Adenosine, and Diltiazem formulations—with a response deadline of April 8, 2026 and an estimated contract value of $40,000, including a 5 percent SLBE bid discount; MMCAP's RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 deadline, effective July 1, 2026, covering multiple state and local facilities across participating states and weighted 75 percent on price competitiveness; and the Texas HHS Commission's RFI (HHS0017013) exploring direct-to-manufacturer prescription programs to inform future formal solicitations. Wholesaler-authorized distribution through AmerisourceBergen, Cardinal Health, and Morris & Dickson characterizes the supply-chain infrastructure underlying current procurements.